TNGX Stock Hits All-Time High – Wolfe Research Calls Tango Therapeutic’s Pancreatic Cancer Trial Data ‘Groundbreaking’
Tango Therapeutics’ experimental cancer drug Vopimetostat, in combination with Daraxonrasib, achieved a 92% objective response rate in patients with advanced pancreatic cancer.